FDA approves first continuous glucose monitoring system with fully implantable sensor
The FDA approved the Eversense Continuous Glucose Monitoring system for use in people 18 years of age and older with diabetes. This is the first FDA-approved CGM system to include a fully implantable sensor to detect glucose, which can be worn for up to 90 days. June 21, 2018